晶泰控股AI药物发现合作达成重要里程碑:Pharmaengine新型Prmt5抑制剂Pep08获得临床试验批准

美股速递
Sep 09, 2025

晶泰控股AI药物发现合作项目取得重要进展,合作伙伴Pharmaengine开发的新型Prmt5抑制剂Pep08成功获得临床试验批准,标志着该合作项目达成重要里程碑。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10